Larazotide
Last reviewed August 7, 2026
Also known as: Larazotide acetate, AT-1001, INN-202
Quick Answer
Larazotide is a zonulin antagonist research compound (not FDA-approved for human use) studied for gut barrier repair. Larazotide is a gut-barrier peptide that blocks the body's 'leaky gut' signaling molecule (zonulin), keeping intestinal tight junctions closed. It has been tested in Phase 3 trials for celiac disease. Research dose: 500–500 mcg 3x daily (with meals). Half-life: 1.5 hours. Available from COA-verified vendors with code PEPTIDEX for up to 20% off.
Where to Source
Ranked by $/mgSourcing data for Larazotide is updating.
We verify new listings weekly — check back soon.
Where to Source
Ranked by $/mgSourcing data for Larazotide is updating.
We verify new listings weekly — check back soon.
Synthetic octapeptide that acts as a zonulin antagonist. Zonulin is the body's primary regulator of intestinal tight junction permeability; elevated zonulin (triggered by gliadin/gluten and dysbiosis)[1]
Where to Buy Larazotide
COA-verified vendors · Use code PEPTIDEX for up to 20% off
Verified pricing for Larazotide is not yet available in our database. Browse all COA-verified vendors on our price comparison tool, or check individual vendor pages.
Compare All Vendors§ Mechanism of Action
Synthetic octapeptide that acts as a zonulin antagonist. Zonulin is the body's primary regulator of intestinal tight junction permeability; elevated zonulin (triggered by gliadin/gluten and dysbiosis) opens tight junctions and causes intestinal permeability ('leaky gut'). Larazotide competitively blocks zonulin receptor binding, preventing tight junction opening and reducing gut permeability without systemic absorption.[1]
§ Primary Benefits
- 1Gut barrier repair
- 2tight junction integrity
- 3celiac disease symptom reduction
- 4leaky gut
§ Clinical Evidence
Larazotide acetate in persistent symptoms of celiac disease: Phase 2b trial
Leffler et al. (JAMA Internal Medicine): Phase 2b RCT — larazotide 0.5mg TID significantly reduced overall celiac disease symptom severity vs placebo in patients on a gluten-free diet, with an excellent safety profile.
StrongLarazotide acetate regulates epithelial tight junctions via a zonulin-independent mechanism
Paterson et al.: Larazotide stabilizes tight junctions and reduces epithelial permeability induced by gliadin, demonstrating its molecular mechanism of action in intestinal barrier protection.
Preclinical§ Safety Profile
Has completed Phase 2b and Phase 3 human trials with excellent safety profile. Minimal systemic absorption (acts locally in gut lumen). Not FDA-approved. Investigational. Phase 3 results have been mixed; FDA application pending review.[2]
See our evidence grading methodology for how we evaluate and grade peptide safety data.
§ Dosing Protocol
* Dosing data from published literature — not a human use recommendation.
RouteOral
Dose Range500–500 mcg
Frequency3x daily (with meals)
TimingWith meals
Cycle Length12–24 weeks
Phase 2b/3 dose: 0.5mg (500mcg) TID with meals. Minimal systemic absorption — acts locally in intestinal lumen.
§ Pharmacokinetics
⏱️ Half-Life: 1.5h
Plasma concentration over time§ Expected Outcomes
Week 1
Reduction in gut permeability markers (zonulin)
Weeks 2–4
Symptom improvement in celiac/IBD research populations
Month 2–3
Sustained tight junction integrity and reduced inflammatory markers
§ Adverse Effects
| Side Effect | Incidence | Severity |
|---|---|---|
Headache | ~8% | mild |
Diarrhea | ~6% | mild |
Where to Source Larazotide for Research
Finding verified, high-purity Larazotide requires rigorous COA verification. We independently evaluate vendors based on third-party HPLC testing, purity thresholds (≥98%), and batch-specific documentation.
View COA-Verified Larazotide✓ Third-party tested·✓ US shipping·✓ COA on every batch
Disclosure: PeptiDex may earn a commission from purchases made through affiliate links. This does not affect our editorial independence or recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
PEPTIDEX coupon for LarazotideSave 20% on Larazotide at Amino Club & verified vendors →
Reconstitution CalculatorCalculate reconstitution for Larazotide →
Compare ToolCompare Larazotide to similar peptides →
Cite This Page
References
2 cited sourcesLast reviewed:
- Larazotide acetate regulates epithelial tight junctions via a zonulin-independent mechanism
- Larazotide acetate in persistent symptoms of celiac disease: Phase 2b trial
All citations link to PubMed (National Library of Medicine). PMIDs are verified weekly via our automated audit system.
⚠️ Educational only · Not medical advice · For research use only. Information on this page is compiled from peer-reviewed literature and is intended strictly for educational and informational purposes. Peptides discussed may be unapproved research chemicals — consult a licensed healthcare professional before considering any peptide compound. Read our full disclaimer
Affiliate disclosure: PeptiDex may earn commissions from purchases made through vendor links on this page. This does not affect our editorial ranking or vendor recommendations — we exclusively feature vendors that pass independent COA verification. See our methodology · Editorial policy
Free Download
2026 Peptide Stack Cheat Sheet
12stacks • exact dosages • cycle lengths • printable reference
No spam. Unsubscribe anytime.
§ About the Author Verified
PeptiDex Research
Independent researcher, not a medical professional
PeptiDex Research is the byline used by the independent researcher who builds and maintains PeptiDex. The site is a one-person research project — there is no editorial board, no medical reviewers, and no clinical staff. Content is produced by reading...
View profileLast fact-checked: · PeptiDex Editorial Team